The polyfunctional alkylating agent thiotepa (N, NЈ, NЉ-Thiotepa (TT) has long been considered for inclusion triethylene thiophosphoramide) (TT) has now been in cliniin clinical bone marrow transplant (BMT) conditioning cal use for more than 40 years. Myelodepression is well regimens in an attempt to prevent allograft rejection recognized as the major dose-limiting toxicity and there is and leukemia relapse. These studies have been encourcurrent interest in applying escalating doses of TT in conaged by initial murine experiments showing a clear junction with autologous bone marrow transplantation improvement in allogeneic bone marrow engraftment (BMT) (eg Refs 1-3). This agent has also been considered with addition of TT to total body irradiation (TBI)
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for inclusion in the conditioning regimen prior to allogeneic where it was assumed that TT enhances donor-type BMT [4] [5] [6] [7] and there is at least experimental evidence for chimerism via ablation of competing stem cells in the enhanced engraftment of donor stem cells when TT was recipient. The aim of the present study was to re-evaluadded to total body irradiation (TBI). 8 The latter finding in ate the hematological toxicity of TT among different an H-2-incompatible allogeneic BMT model in mice was stem cell subsets that included primitive cells capable attributed to the reduction of stem cell competition through of long-term repopulation and to assess how the combiadditional myeloablation and this effect has been compared nation of TT with TBI influences the development of with host stem cell toxicity afforded by another alkylating donor engraftment in both syngeneic (B6-Gpi-1 a → B6-agent, busulfan. However, it has since been appreciated that Gpi-1 b ) and H-2 compatible allogeneic (BALB.B10 → while the acute myelodepression caused by various cyto-B6) BMT models. At 24 h after TT (20 mg/kg) the femtoxic agents generally reflects depletion of committed prooral content of different stem cell subsets was detergenitor cell populations in the bone marrow, it may not mined from the frequency of transient repopulating, necessarily follow that primitive stem cells capable of longand the more primitive cobblestone area-forming, cells term repopulation are similarly affected. 9-11 The aim of the (CAFCs) growing in stroma-supported cultures. This present study was to re-address the hematological properassay showed a large TT-induced depletion (2% ties of TT with respect to survival of the different progenisurvival) of early clones developing at day 7 in culture tor and stem cell subsets in the mouse bone marrow by but survival recovered towards normal for later appearenumerating cobblestone area-forming cell (CAFC) subsets ing clones developing from more primitive CAFC subafter treatment. We then evaluated how the combination of sets. The sparing of these primitive stem cells was TT with TBI influences the magnitude of short-and longreflected as undetectable levels of donor marrow term engraftment of transplanted marrow cells using conrepopulation in recipients given TT followed by syngenically marked B6-Gpi-1 a donors where hemopoietic geneic BMT. Addition of TT to TBI did not significantly stem cells represent the principle targets for achieving improve long-term engraftment of syngeneic marrow engraftment. This was finally compared with transplanwhile this combination had a dramatic effect in allotation across an H-2-compatible genetic barrier (equivalent geneic BMT by preventing allograft rejection. In this to HLA-matched allogeneic BMT in the human) where respect TT shares similar properties with cyclophosthere is the additional need to suppress immunity and phamide and suggests that the large improvement of induce a state of tolerance for growth of allogeneic bone allogeneic stem cell engraftment is attributable to the marrow. immune suppressive properties of TT rather than to its toxicity against host primitive stem cells. Keywords: thiotepa; total body irradiation; marrow Materials and methods transplantation; chimerism; stem cell ablation; immune suppression Male C57BL/6JIco (B6-Gpi-1 ), but mismatched on a number of minor histocompatibility loci.
Thiotepa (TT) (Wyeth Lederle, Pearl River, NY, USA) was dissolved in phosphate-buffered saline (PBS) and injected i.p. at a single bolus of 20 mg/kg. Preliminary pilot experiments had established that this approximated to the maximal tolerated dose when higher doses resulted in lethal gastrointestinal toxicity. Cyclophosphamide (CY) (AldrichChemie, Steinheim, Germany) was dissolved in PBS and administered i.p. at a single dose of 200 mg/kg. Total body irradiation was delivered using a 137 Cs ␥-irradiation unit (IBL 637; CIS Biointernational, Gif-sur-Yvette, France) at a dose rate of 87 cGy/min to a dose of 5 Gy. Previous studies had established that this radiation dose is close to the lower threshold for H-2-compatible allo-engraftment while higher doses are required in H-2-incompatible BMT.
12-14 TBI was given either alone or at 24 h before TT or CY. After TT treatment the mice were maintained on neomycin (3.5 g/l sterile drinking water) for 2 weeks to minimize the possible problems of endotoxemia via gut toxicity.
The CAFC assay was performed on harvested bone marrow pooled from groups of three to four mice at 24 h after treatment as previously described 15 with minor modifications. Briefly, bone marrow suspensions were plated at limiting dilutions on confluent layers of the bone marrow stromal cell line FBMD-1 in 96-well plates. This culture system supported growth of different CAFC subsets representing a time-related descendency of cells in the hemopoietic hierarchy where CAFC day-7 corresponds to CFU-GM , CAFC day-14 to CFU-S day-12 and CAFC days 28-35 to the most primitive stem cells with long-term repopulating ability (CAFC days 28-35).
15-17
At 24 h after TT or CY or at 48 h after TBI, allocated mice were transplanted i.v. with 10 6 nucleated bone marrow mined using glucose phosphate isomerase (GPI-1) activity
Bone marrow harvests were pooled from groups of three to four B6 mice as already described. given in Figure 1a to show a large TT-induced depletion (2% survival) of CAFCs developing early at day 7. Survival from this drug progressively improved for later developing The effect of combining TT and TBI on the subsequent engraftment of syngeneic marrow cells is shown in Figure  CAFC subsets approaching a near-normal value for CAFC day 35. For comparison, earlier CAFC data are shown fol2a where TT significantly enhanced donor-type blood chimerism during the first 10 weeks, presumably due to lowing TBI or CY treatment where the former appeared to be effective at depleting all day-types while the latter had the additive toxicity of radiation and TT to the short-term repopulating progenitor populations in the recipient maran overall small effect on these subsets. The data presented in Figure 1a is reflected in the patterns of syngeneic donorrow. However, at times beyond 10 weeks the levels in the TT + TBI group were not significantly higher than the type chimerism as given in Figure 2b . Thus by depleting a large proportion of the early day type CAFC compartment engraftment given by TBI alone. The effect of adding an immunological barrier in the allogeneic BMT combination both TT and TBI pretreatment led to high levels of shortterm engraftment but only radiation was capable of produis shown in Figure 2b where TBI alone produced only a short period of transient engraftment indicating complete cing maintained levels of chimerism through depletion of primitive CAFCs in the host.
allograft rejection and full repopulation from residual host
Discussion
With the assumption that thiotepa (TT) has similar myeloablative properties to radiation or busulfan, Terenzi et al 8 presented results in a fully mismatched allogeneic BMT model (B6-H-2 b → C3H-H-2 k , 3 × 10 6 BMC) that clearly showed an improvement in donor engraftment when TT (10 mg/kg) was added to TBI (8 Gy) in the conditioning regimen. These authors interpreted these results in terms of reduction of stem cell competition through additional myeloablation. However, to achieve lasting levels of donor-type chimerism requires the eradication of true long-term repopulating stem cells but this small subset has remained difficult to measure until the arrival of quantitative methods such as the CAFC assay. In view of our own interests in selecting busulfan analogues for potency against primitive stem cells, we have incorporated TT in our CAFC and syngeneic BMT studies and clearly showed that while TT is toxic to committed progenitor populations (early developing CAFCs) and can promote early donor engraftment, primitive stem cells (late developing CAFCs) remained relatively resistant to this drug leading to longterm host marrow repopulation and disappearance of donor engraftment. In this respect TT has similar properties to other chemotherapeutic agents such as 5-FU and melphalan but is in complete contrast to the preferential killing of late developing CAFC subsets by busulfan and other dimesylate compounds.
9,10
TT had its greatest impact when combined with TBI in our H-2-compatible allogeneic model by reducing allograft rejection and this is entirely consistent with the previous findings in H-2 incompatible BMT.
8 TT was also comparable to the allograft-promoting effects of CY which is well recognized for its potent immunosuppressive properties. These data in mice are not, however, supported by results on allogeneic graft failure in rats given combinations of busulfan with TT, where TT appeared not to prevent rejec- a large variation in the effectiveness of CY depending on its sequence and timing with TBI 12 and it thus remains conceivable that alterations in the TT schedule may share similar problems.
While the differences are relatively small and statistically stem cells. In this case TT clearly improved both short-and insignificant, it is of interest to note that addition of either long-term engraftment and this was slightly higher than the TT or CY appeared to produce slightly more allogeneic effect of adding CY. engraftment than expected from syngeneic BMT. A similar Recipient mice survived in good health through the 5 phenomenon has been seen by raising the radiation dose.
14 months post-BMT except for a brief period of diarrhea durSuch conditions could allow for extra stem cell killing in ing the first week after TT treatment and the loss of the the recipient bone marrow from alloreactive T cells in the lower incisors in the group receiving TBI and CY. The donor graft thus providing more of a competitive advantage latter resulted in body loss due to malnutrition and required for transplanted stem cells. the supply of a softened diet at 10 weeks after treatment.
In conclusion, our data showing both resistance of late By 20 weeks the teeth regrew but with gross abnormalities.
developing CAFCs and enhancement of engraftment only Incisor toxicity after TBI and CY combinations have been in the presence of an immunological barrier strongly sugdocumented before 12 and presumably reflects the high sengest that, similar to CY, the effectiveness of TT in allogeneic graft tolerance is largely due to its immune suppresssitivity of this rapidly renewing tissue in rodents. 
